Hints and tips:
Related Special Reports
...Gareth Powell, head of healthcare at specialist fund manager Polar Capital, said mRNA was following previous platforms such as antibodies, in which investors would get excited about developers initially...
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
...The US pharmaceutical company has agreed to extend its contract from 2023 to 2026, according to two people with knowledge of the talks....
...The abandoned asundexian trial “is a major setback for Bayer”, said Markus Manns, a portfolio manager and healthcare expert at Union Investment, Germany’s third-largest asset manager....
...Metagenomi, a pre-clinical group backed by Moderna and Bayer, priced its $94mn IPO last week at the bottom of its target range, and fell 31 per cent on its first day of trading on Friday....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...They produce prescription drugs against cancer, heart disease and other illness, over-the-counter healthcare products like Bepanthen cream as well as seeds and herbicides for farmers....
...He said chancellor Jeremy Hunt and the health department should address conflicts with the pharmaceutical industry over drug prices and hurdles to running clinical trials in the NHS....
...They put a lot of strain on healthcare systems,” she told the Financial Times....
...The Medicines and Healthcare products Regulatory Agency, the UK drugs watchdog, is assessing whether conditional marketing authorisation should be renewed for Merck’s molnupiravir, also known by the trade...
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
...The US government named 10 of the best-selling drugs as the first to face tough price regulations in a bid to slash healthcare costs, marking the biggest shake-up for the pharmaceutical industry in decades...
...Bayer has said it is shifting the focus of its pharmaceutical business to the US and away from Europe and the UK, where governments are making “big mistakes” in how they manage health budgets....
...The reforms have been fiercely resisted by the pharmaceutical industry, which has warned they would cripple innovation and hinder development of life-saving medicines....
...However, the FTC’s case against Amgen is targeted at the power the company allegedly wields more broadly with health insurers and middlemen in the US healthcare system, known as pharmacy benefit managers...
...healthcare and crop science....
...Ginger Graham, a board member since 2010 and former chief of Amylin Pharmaceuticals, will fill the chief executive role while it searches for “a successor with deep healthcare experience”....
...Healthcare spending accounts for about a fifth of US economic output. Competition authorities want to restrain its cost growth....
...For the GSK legal team, this meant recasting itself to support a smaller, more focused pharmaceutical business....
...Shares of Kenvue, the consumer arm of healthcare giant Johnson & Johnson, jumped on their first day of trading after an upsized initial public offering that marked the biggest US listing in almost 18 months...
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...The world’s biggest healthcare products company said on Tuesday it was unfortunate that it had to pay claimants for what it described as “baseless scientific claims” but noted that protracted litigation...
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
...The FT’s US pharmaceutical correspondent Jamie Smyth helps us explore whether J&J’s use of this manoeuvre is setting a precedent for corporations to evade accountability in America....
International Edition